Generic Name and Formulations:
Ezetimibe 10mg; tabs.
Merck & Co., Inc.
Indications for ZETIA:
Adjunct to diet, alone or in combination with an HMG-CoA reductase inhibitor (statin), in primary hyperlipidemia (heterozygous familial and non-familial) to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C. Adjunct to diet and in combination with fenofibrate to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in mixed hyperlipidemia. Adjunct to other lipid-lowering treatments, or if these treatments are unavailable, with atorvastatin or simvastatin to reduce elevated total-C and LDL-C in homozygous familial hypercholesterolemia. Adjunct to diet in homozygous familial sitosterolemia to reduce elevated sitosterol and campesterol.
≥10yrs: 10mg once daily. Concomitant bile acid sequestrants: give ezetimibe either ≥2hrs before or ≥4hrs after. Concomitant simvastatin doses >20mg in moderate-to-severe renal impairment: use caution and monitor closely.
<10yrs: not recommended.
The use of ezetimibe with a statin is contraindicated in active liver disease or unexplained persistent elevations in serum transaminases. Statins are contraindicated in pregnancy and nursing.
Moderate to severe hepatic insufficiency: not recommended. If given with a statin: monitor liver function initially and then as recommended for the statin. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Cholesterol absorption inhibitor.
Concomitant fibrates (except fenofibrate): not recommended. Potentiates cyclosporine. Potentiated by fenofibrate, gemfibrozil, cyclosporine. Monitor warfarin, cyclosporine. Antagonized by cholestyramine.
Upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, dizziness, headache, fatigue; rare: myopathy/rhabdomyolysis; w. statin: nasopharyngitis, myalgia, back pain, increased serum transaminases.
For more information on statins, see their entries.
Tabs—30, 90, 500, 5000
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|